IL-33 receptor inhibition in subjects with uncontrolled asthma: A randomized, placebo-controlled trial

BACKGROUND: Most biologics for severe asthma target only type 2 immunity. Inhibition of IL-33 signaling has the potential to target type 2 and non–type 2 pathways. OBJECTIVE: This multicenter phase IIA study evaluated the safety and efficacy of GSK3772847, a human mAb directed against the IL-33 rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Crim, Courtney, Stone, Sally, Millar, Valerie, Lettis, Sally, Bel, Elisabeth H., Menzies-Gow, Andrew, Chanez, Pascal, Wenzel, Sally, Lugogo, Njira, Bleecker, Eugene R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509964/
https://www.ncbi.nlm.nih.gov/pubmed/37779541
http://dx.doi.org/10.1016/j.jacig.2022.07.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509964/
https://www.ncbi.nlm.nih.gov/pubmed/37779541
http://dx.doi.org/10.1016/j.jacig.2022.07.002

Ejemplares similares